Cancer Genetics

Cancer Genetics, Inc. (CGI) provides DNA-based cancer diagnostics and services to medical institutions. The Company's tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services. CGI’s tests and reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. The Company's reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited.

Company Growth (employees)
Rutherford, US
Size (employees)
142 (est)-36%
Cancer Genetics was founded in 1999 and is headquartered in Rutherford, US

Key People at Cancer Genetics

Panna Sharma

Panna Sharma

President & CEO

Cancer Genetics Office Locations

Cancer Genetics has offices in Rutherford, Morrisville, Los Angeles, Shanghai and in 1 other location
Rutherford, US (HQ)
Complex 201 Route 17 North
Shanghai, CN
Zhong Guo Yi Dong ( Cai Lun Lu )
Los Angeles, US
Health Research Association 1640 Marengo St
Morrisville, US
133 Southcenter Ct

Cancer Genetics Data and Metrics

Cancer Genetics Financial Metrics

Cancer Genetics's revenue was reported to be $7 m in Q1, 2017

Revenue (Q1, 2017)

7 m

Gross profit (Q1, 2017)

2.8 m

Gross profit margin (Q1, 2017), %


EBIT (Q1, 2017)

(2.8 m)

Market capitalization (22-Sep-2017)

57.9 m

Cash (31-Mar-2017)

9.7 m
Cancer Genetics's current market capitalization is $57.9 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


6.6 m10.2 m18 m27 m

Revenue growth, %


Cost of goods sold

4.9 m8.5 m14.1 m17.1 m

Gross profit

1.7 m1.7 m3.9 m9.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


1.5 m3.2 m4.4 m4.2 m4 m6.1 m7 m6.8 b7 m

Cost of goods sold

1.5 m2.6 m3.1 m3.1 m3.1 m4.1 m4.3 m4.4 b4.2 m

Gross profit

8.6 k656.1 k1.2 m1.1 m897.1 k2 m2.7 m2.3 b2.8 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


49.5 m25.6 m19.5 m9.5 m

Current Assets

51.9 m31.8 m28.2 m23.4 m


1.3 m4.4 m6.1 m4.7 m


3 m12 m12 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


23.7 m19.9 m13.3 m10.6 m10.7 m9.7 m

Current Assets

31.1 m3.8 m23.5 m24.5 m26.6 m24.4 m


3.9 m5.9 m5.4 m4.9 m4.8 m


3.2 m3.2 m12 m12 m12 m12 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.4 m)(16.6 m)(20.2 m)(15.8 m)

Depreciation and Amortization

311.2 k810.2 k1.5 m2 m

Accounts Receivable

(716.5 k)(1.7 m)(1.7 m)(5.9 m)

Cash From Operating Activities

48.6 m(23.9 m)(6.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(6.7 m)

Depreciation and Amortization

214.5 k487.7 k347.7 k679.6 k971.2 k518 k1 m1.5 m534 k

Accounts Receivable

(489.2 k)(521.4 k)(17.2 k)(909.9 k)(349.4 k)(1.8 m)(5.3 m)(7.1 m)(901 k)

Purchases of PP&E

(385.2 k)(944.4 k)(83.1 k)(257.5 k)(439.7 k)(319 k)(319 k)(345 k)(178 k)
USDY, 2017


38.2 k

Financial Leverage

2.1 x
Show all financial metrics

Cancer Genetics Market Value History

Traffic Overview of Cancer Genetics

Cancer Genetics Online and Social Media Presence

Cancer Genetics Company Life and Culture

You may also be interested in